Model-Based Meta-Analysis (MBMA) Archives | 第 2 页，共 5 页 | Certara

On-Demand Webinar

Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]

Vice President, Quantitative Science Services, Certara Matt advances the integration of published clinical outcomes data…

Certara2025 年 4 月 3 日

Publication

The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement

This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…

Certara2025 年 2 月 25 日

Fact Sheet

定量药理学在药物开发中的决策支持：基于模型的荟萃分析（MBMA）

Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…

Certara2025 年 2 月 19 日

On-Demand Webinar

利用基于模型的荟萃分析 (MBMA) 解决药物开发难题

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

Certara2025 年 1 月 9 日

Publication

INTERCEPT-AD：一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

Certara2025 年 1 月 8 日

Poster

临床前数据暴露无法预测双特异性 T 细胞吸引剂在实体瘤适应症中的临床生理活性剂量；是否有更好的衡量标准？— 来自小型机制性 MBMA 的启示

Certara2024 年 12 月 11 日

Amgen

Case Study

使用 MBMA 进行虚拟 "正面交锋试验"

Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…

Certara2023 年 4 月 21 日

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

Certara2021 年 12 月 15 日

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

Certara2019 年 12 月 19 日

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

Certara2018 年 6 月 2 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software